Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

312
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
312
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Dementia01:30

Dementia

182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
182

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between physical fitness and semen quality: a cross-sectional study in a Spanish male cohort.

Reproductive biomedicine online·2026
Same author

Sit-to-stand test emerges as a powerful prognostic factor of future health outcomes: different versions, measurement properties and future perspectives.

British journal of sports medicine·2026
Same author

Effects of a 24-week resistance exercise program on Alzheimer's disease brain signatures in cognitively unimpaired older adults: a secondary analysis of the AGUEDA randomized controlled trial.

Age and ageing·2026
Same author

Effects of a 24-week resistance exercise program on brain amyloid and Alzheimer's disease blood-based biomarkers: the AGUEDA randomized controlled trial.

medRxiv : the preprint server for health sciences·2026
Same author

Sleep Behaviors and the Shape of Subcortical Brain Structures in Children with Overweight/Obesity: A Cross-Sectional Study - Authors' Reply-2.

Indian journal of pediatrics·2026
Same author

Effects of a Bone-Strengthening Exercise Intervention on Bone Health in Pediatric Cancer Survivors: A Randomized Controlled Trial.

Archives of physical medicine and rehabilitation·2026

Related Experiment Video

Updated: Sep 19, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.5K

Interplay between physical activity, tau pathophysiology, and cognition.

Marcos Olvera-Rojas1, Francisco B Ortega2, Irene Esteban-Cornejo3

  • 1Department of Physical Education and Sports, Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain.

Trends in Neurosciences
|June 6, 2025
PubMed
Summary

Regular physical activity (PA) may protect against Alzheimer's disease (AD). Higher PA levels correlate with lower levels of phosphorylated tau (ptau) 217, suggesting a link to tau pathology and better cognitive function.

Keywords:
Alzheimer’s diseasedementiaexerciseneuroscienceplasma biomarkersptau217

More Related Videos

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.7K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.5K

Related Experiment Videos

Last Updated: Sep 19, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.5K
A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

3.7K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.5K

Area of Science:

  • Neuroscience
  • Gerontology
  • Public Health

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Physical activity (PA) is a recognized modifiable factor influencing AD risk.
  • Emerging evidence suggests a link between PA and AD neuropathology.

Purpose of the Study:

  • To investigate the association between physical activity levels and Alzheimer's disease biomarkers.
  • To explore the relationship between PA, tau pathophysiology, and cognitive function in AD.

Main Methods:

  • Cross-sectional study design.
  • Assessment of physical activity levels.
  • Measurement of cerebrospinal fluid (CSF) or plasma phosphorylated tau (ptau) 217 concentrations.
  • Evaluation of β-amyloid (Aβ) brain uptake.
  • Cognitive function assessment.

Main Results:

  • Higher levels of physical activity were significantly associated with reduced ptau-217 concentrations.
  • This association remained significant after adjusting for β-amyloid (Aβ) brain uptake.
  • The relationship between PA and reduced ptau-217 mediated better general cognitive performance.

Conclusions:

  • Physical activity may exert protective effects against Alzheimer's disease by influencing tau pathophysiology.
  • PA is a potential therapeutic target for mitigating AD progression and preserving cognitive function.